NCT07897708
A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Timeframe: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Serious Adverse Events (SAEs)
Timeframe: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Laboratory Abnormalities
Timeframe: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Vital Signs Abnormalities
Timeframe: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
Timeframe: From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Columbia-Suicidality Severity Rating Scale (C-SSRS)
Timeframe: From first dose through approximately 28 to 35 days after the last dose
Secondary (7)
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)
Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)
Maximum Observed Plasma Concentration (Cmax)
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) if data permit
Show 2 moreShow less
Plasma Decay Half-life (t1/2) if data permit
Cerebrospinal Fluid (CSF) Concentration of PF-08161842
Arms and interventions
Part A: Cohorts 1-6 and 7 (optional)Experimental
Participants will receive PF-08161842 or matching placebo as a single dose on Day 1.
Part B: Cohort 8-12 and 13 (Optional)Experimental
Participants will receive doses of PF-08161842 or matching placebo from Day 1 through Day 14.
Drugs: PF-08161842, Placebo for PF-08161842